Identifying states of collateral sensitivity during the evolution of therapeutic resistance in Ewings sarcoma
J. A. Scarborough, E. McClure, P. Anderson, A. Dhawan, A. Durmaz, S. L. Lessnick, M. Hitomi, J. G. Scott
Abstract
Advances in the treatment of Ewings sarcoma (EWS) are desperately needed, particularly in the case of metastatic disease. A deeper understanding of collateral sensitivity, where the evolution of therapeutic resistance to one drug aligns with sensitivity to another drug, may improve our ability to effectively target this disease. For the first time in a solid tumor, we produced a temporal collateral sensitivity map that demonstrates the evolution of collateral sensitivity and resistance in EWS. We found that the evolution of collateral resistance was predictable with some drugs, but had significant variation in response to other drugs. Using this map of temporal collateral sensitivity in EWS, we can see that the path towards collateral sensitivity is not always repeatable, nor is there always a clear trajectory towards resistance or sensitivity. Identifying transcriptomic changes that accompany these states of transient collateral sensitivity could improve treatment planning for EWS patients.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Leveraging Experimental Evolution to Extract Predictive Collateral Drug Response Signatures in Ewings Sarcoma
Kristi Lin‐Rahardja, Ethan Canavan, Jacob G. Scott·bioRxiv·Sep 19, 2025
- EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism
J. Olmedo-Pelayo, E. L. Granado-Calle, … E. de Alava·bioRxiv·May 30, 2023
- Collateral sensitivities with predictive signatures emerge in a novel model of evolved chemoresistance in osteosarcoma
Zachary D. C. Burke, Kristi Lin‐Rahardja, … Jacob G. Scott·bioRxiv·Aug 11, 2026
- SLFN11 Loss-Induced Chemoresistance is Associated with Overexpression of Glycerophospholipid Biosynthesis in Ewing Sarcoma.
Kasturee Chakraborty, Ritambhar Burman, … Puneet Bagga·bioRxiv·May 9, 2025
- Transcriptional Rewiring of BET Inhibitor Treated Ewing Sarcoma Cells Augments their Dependency on Focal Adhesion Kinase
Shireen S. Ganapathi, Emma D. Wrenn, … Elizabeth R. Lawlor·bioRxiv·Sep 2, 2025
- Dynamic modelling of EWS::FLI1 fluctuations reveals molecular determinants of phenotypic tumor plasticity and prognosis in Ewing sarcoma
Veveeyan Suresh, Christoph Hafemeister, … Valerie Fock·bioRxiv·Apr 3, 2025